Accelerating progress towards tuberculosis elimination: The need for combination treatment and prevention

International Journal of Tuberculosis and Lung Disease

Volumn 19, Issue 1, 2015, Pages 5-9

  Reid, A ^a   Grant, A D ^b   White, R G ^b   Dye, C ^c   Vynnycky, E ^b,d   Fielding, K ^b   Churchyard, G ^b,e,f   Pillay, Y ^g  

^a Joint United Nations Programme on HIV AIDS (UNAIDS)   (South Africa)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

^d PUBLIC HEALTH ENGLAND   (United Kingdom)

^e AURUM INSTITUTE   (South Africa)

^f UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^g NATIONAL DEPARTMENT OF HEALTH   (South Africa)

Author keywords

Modelling; Policy; Tuberculosis

Indexed keywords

ANTIRETROVIRUS AGENT; ISONIAZID; TUBERCULOSTATIC AGENT;

BACTERIAL TRANSMISSION; COMBINATION CHEMOTHERAPY; DISEASE ELIMINATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; LATENT TUBERCULOSIS; MATHEMATICAL MODEL; MINING; MORTALITY; POPULATION MODEL; REVIEW; SILICOSIS; SOUTH AFRICA; TUBERCULOSIS; TUBERCULOSIS CONTROL; CLUSTER ANALYSIS; COMPLICATION; DRUG COMBINATION; HIV INFECTIONS; PREVALENCE; THEORETICAL MODEL;

ANTI-RETROVIRAL AGENTS; ANTITUBERCULAR AGENTS; CLUSTER ANALYSIS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; INCIDENCE; MODELS, THEORETICAL; PREVALENCE; TUBERCULOSIS;

EID: 84918772496     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.14.0078     Document Type: Review

References (16)

1. World Health Organization. Global tuberculosis report 2013. WHO/HTM/TB/2013.11. Geneva, Switzerland: WHO, 2013. http://www.who.int/tb/publications/global-report/en/. Accessed September 2014.
2. nd meeting. Geneva, Switzerland: World Health Organization, 2012. http://www.stoptb.org/news/stories/2012/ns12-073.asp. Accessed September 2014.
3. De Cock K M, Chaisson R E. Will DOTS do it? A reappraisal of tuberculosis control in countries with high rates of HIV infection. Int J Tuberc Lung Dis 1999;3:457-465.
4. World Health Organization. The Stop TB Strategy: building on and enhancing DOTS to meet the TB-related Millenium Development Goals. Geneva, Switzerland: WHO, 2006. http://whqlibdoc.who.int/hq/2006/WHO-HTM-STB-2006.368-eng.pdf. Accessed September 2014.
5. World Health Organization. Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. Geneva, Switzerland: WHO, 2011. http://whqlibdoc.who.int/publications/2011/9789241500708-eng.pdf. Accessed September 2014.
6. World Health Organization. WHO policy on collaborative TB/HIV activities: Guidelines for national programmes and other stakeholders. WHO/HTM/TB/2004.330; WHO/HTM/HIV/2004.1. Geneva, Switzerland: WHO, 2012. http://www.who. int/tb/publications/2012/tb-hiv-policy-9789241503006/en/index.html. Accessed September 2014.
7. Suthar A B, Lawn S D, Del Amo J, et al. Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLOS MED 2012;9:e1001270.
8. Dye C, Glaziou P, Floyd K, Raviglione M. Prospects for tuberculosis elimination. Ann Rev Public Health 2013;34:271-286.
9. Vynnycky E, Sumner T, Fielding K L, et al. Tuberculosis control in South African goldmines: mathematical modelling of a trial of community-wide isoniazid preventive therapy. AJE 2014 [In press].
10. Rangaka M X, Boulle A, Wilkinson R J, et al. Randomised controlled trial of isoniazid preventive therapy in HIV-infected persons on antiretroviral therapy. XIX International AIDS Conference, Washington DC, USA, 22-27 July 2013 [abstract THLBB03].
11. Boehme C C, Nicol M P, Nabeta P, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpertw MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 2011;377:1495-1505.
12. Dorman S E, Chihota V N, Lewis J J, et al. Performance characteristics of the Cepheid Xpertw MTB/RIF test in a tuberculosis prevalence survey. PLOS ONE 2012;7:e43307.
13. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV-infected persons. Cochrane Database Syst Rev 2010; (1): CD000171.
14. Smieja M J, Marchetti C A, Cook D J, Smaill F M. Isoniazid for preventing tuberculosis in non-HIV-infected persons. Cochrane Database Syst Rev 2000; (2): CD001363.
15. Joint United Nations Programme on HIV and AIDS. Practical Guidelines for intensifying HIV prevention: towards universal access. UNAIDS/07.07E/JC1274E. Geneva, Switzerland: UNAIDS, 2012. http://data.unaids.org/pub/Manual/2007/20070306-prevention-guidelines-towards-universal-access-en.pdf. Accessed September 2014.
16. Vynnycky E, Fine P E. Interpreting the decline in tuberculosis: the role of secular trends in effective contact. Int J Epidemiol 1999;28:327-334.